EU approval for Eisai's first-in-class anti-epileptic perampanel
This article was originally published in Scrip
Executive Summary
Eisai is to launch its novel epilepsy product perampanel (Fycompa) in its first market, the UK, in September this year after it received approval in the EU. The news came just a day after the company published data from the second out of three pivotal Phase III studies that formed the basis of US and European submissions.